
    
      OVERVIEW OF TRIAL DESIGN

      This FOCULM trial is a a two-arm, multicenter, open labelled, prospective, randomized phase
      II studies. Eligible patients with initially unresectable liver-limited mCRC will be
      randomised 1:1 to receive either FOLFOXIRI plus bevacizumab or FOLFOXIRI alone.
    
  